On 25 May 2004, the US Food and Drug Administration (FDA) published in the Federal Register a final rule establishing criteria for donors of human cells, tissues and cellular- and tissue-based products (HCT/Ps), to be implemented under the proposed comprehensive regulatory framework for HCT/Ps1-3. The rule also amends the current good manufacturing practice (cGMP) and quality systems (QS) regulations that apply to HCT/Ps regulated as drugs, medical devices and/or biologics, to clarify the role of the new donor-eligibility regulations in relation to existing cGMP regulations.
The rule extends the requirements for screening and testing, already incumbent on establishments dealing with human tissue intended for transplantation, such as muscular, skin and ocular tissue, to those dealing...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?